{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" No specific ethnic group mentioned in the text.", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" \"ETHNIC GROUP\": []\n\nNo specific ethnic group information was provided in the text.", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" No ethnic group information provided in the text.", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" \"ETHNIC GROUP\": []", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in the text)", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"ETHNIC GROUP\": [\"\"]\n\nThis passage does not refer to any specific ethnic group. It is discussing cancer patients in general.", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" \"ETHNIC GROUP\": []", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group was mentioned in the text)", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"ETHNIC GROUP\": []\n\nPGx (pharmacogenomics) is a field of study and not an ethnic group.\n\nHowever, the text mentions that the patient took cannabis.\n\n\"ETHNIC GROUP\": [\"Not specified in text\"]\n\n\"CANNABIS\": [\"Cannabis\"]", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group. It discusses Parkinson's Disease (PD) and the treatment strategies for it, which can be applied to any ethnic group affected by PD.", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" \"ETHNIC GROUP\": [\"\"]\n\n(It is important to note that the term \"ethnic group\" can be misleading in this context, as it is not explicitly stated in the text that the individuals in question belong to specific ethnic groups. The text is discussing the importance of considering pharmacogenomic data for patients in general.)", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" \"ETHNIC GROUP\": []\n\nThe text does not provide any information about the ethnic group of the patient.", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" No ethnic group information provided in this text.", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" No specific ethnic group mentioned in this text.", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" No specific ethnic group mentioned in the text.", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific reference to an ethnic group.", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" \"ETHNIC GROUP\": [\"\"]\n\n(PGx stands for Pharmacogenomics, it is a field of genetics that studies how genes affect a person's response to drugs. It does not refer to an ethnic group.)", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"ETHNIC GROUP\": [\"Patients with Parkinson's Disease\"]", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" \"ETHNIC GROUP\": []\n\n(No ethnic group information was provided in the text related to this citation.)", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" \"ETHNIC GROUP\": []", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis sentence does not provide any specific information about ethnic groups.", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" \"ETHNIC GROUP\": [\"South Korean\"]", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" \"ETHNIC GROUP\": []", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" \"ETHNIC GROUP\": []", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: Pharmacogenomics studies are not specific to any ethnic group)", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific ethnic group information. It only mentions the significance of the SNP in the thiopurine S-methyltransferase (TPMT) gene in relation to the hypoglycemic effect of the drug.", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" No ethnic group information provided in the text.", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" {\"AUC\": [\"concentration-time curve\"],\n \"EMs\": [\"extensive metabolizer\"],\n \"PM\": [\"poor metabolizer\"]}", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" No specific ethnic group mentioned in the text.", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" \"ETHNIC GROUP\": [\"Cameroonian\", \"Ghanaian\", \"Nigerian\", \"Togolese\"]", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific ethnic group information.", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" \"ETHNIC GROUP\": [\"African\"]", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" No specific ethnic group mentioned in the text.", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" No specific ethnic group mentioned in the text.\n\n{\"ETHNIC GROUP\": []}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide any specific information about ethnic groups related to herbal medicinal remedies or DDI studies.", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" No specific ethnic group mentioned in the text.", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" No ethnic group mentioned in the text.", {}]], [38, "[44].", [" It is unclear what entity is referred to in this citation as no information is provided in the text. Therefore, no entry should be added for this citation.", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" \"ETHNIC GROUP\": [\"N/A\"]\n\nThis passage does not contain any specific reference to ethnic groups. It mentions the brands and locations of the companies that manufactured and supplied the equipment used in the experiments.", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" No specific ethnic group information was provided in the text.", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" {\"ETHNIC GROUP\": []}", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" No specific ethnic group mentioned in the text.", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis passage does not provide any specific information about ethnic groups. It is discussing the pharmacokinetic profile of Danshen components and the potential role of various transporter families in their absorption and elimination.", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" \"ETHNIC GROUP\": [\"Community\"]", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"ETHNIC GROUP\": [\"Diabetic patients\"]", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was provided in the text.", {}]], [47, "Elliot et al.", [" \"ETHNIC GROUP\": []", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"ETHNIC GROUP\": [\"Not specified in the text\"]", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" \"ETHNIC GROUP\": [\"Human\"]", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was mentioned in this sentence.", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" This is not an ethnic group. It is a year.", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"ETHNIC GROUP\": []\n\nThis passage does not provide any information about ethnic groups. It discusses the impact of a specific genetic variant (CYP2C9*3) on drug metabolism.", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" \"ETHNIC GROUP\": [\"Korean\"] (assuming Park is a Korean last name)", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" \"ETHNIC GROUP\": []", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any details about ethnic groups. It is about laboratory test results.", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group.", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" No specific ethnic group information is provided in the given text.\n\n{\"ETHNIC GROUP\": []}", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"ETHNIC GROUP\": [\"American\"]", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" No specific ethnic group mentioned in this statement.", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group. It is a general scientific concept.", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis entity does not refer to an ethnic group. It is a reference to the Naranjo Adverse Drug Reaction Causality Scale.", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"ETHNIC GROUP\": [\"Not specified in the text\"]", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" \"ETHNIC GROUP\": []\n\nThis sentence does not provide any information about ethnic groups. It is about a specific antibiotic called Levofloxacin, which is used to treat bacterial infections.", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" \"ETHNIC GROUP\": [\"Chinese\"]\n\n\"POLYGONUM CAPITATUM\": []\n\n\"RELINQING\u00ae GRANULE\": []\n\n\"LVFX\": []\n\n[Note: I couldn't find any specific ethnic group mentioned in this context, but it's most likely referring to Traditional Chinese Medicine practices.]", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" No specific ethnic group mentioned in the text.", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" No ethnic groups mentioned in this text.", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" No ethnic group information provided in this text.", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" No ethnic group information provided in this text.", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" No specific ethnic group mentioned in the text.", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group.", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" \"ETHNIC GROUP\": []", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" No ethnic group information provided.", {}]], [74, "KY[2017]073).", [" This text does not contain any mention of an ethnic group.", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" \"ETHNIC GROUP\": [\"People with diabetes\"]", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" \"ETHNIC GROUP\": []\n\nThe article does not provide information about the ethnic group related to KF (Kudzu Fermented extract or Kudzu).", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" \"ETHNIC GROUP\": [\"\"]}\n\nThese entities are not related to any specific ethnic group. They are commercial products from a company based in the United States.", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" \"ETHNIC GROUP\": []\n\nDigoxin is a cardiac glycoside medication.\n\"COMPOUND\": [\"digoxin\"]\n\n\"MEDIA\": [\"DMEM\", \"FBS\", \"non-essential amino acids\"]\n\n\"EQUIPMENT\": [\"96-well microplates\"]\n\n\"UNITS\": [\"200 \u03bcL\"]", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific ethnic group information.", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide any information about ethnic groups.", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" No ethnic group information provided in this text.", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group. It is discussing the metabolism of drugs and the role of certain cytochrome P450 enzymes.", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" \"ETHNIC GROUP\": [\"None\"]\n\nThe text does not mention any specific ethnic group related to rooibos or the conditions it is relevant to.", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group. It is a general statement about flavonoids and their interaction with certain enzymes.", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" No ethnic group information provided in this text.", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" \"ETHNIC GROUP\": []\n\nThis passage does not contain any specific reference to ethnic groups.", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"ENZYME\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]\n\n\"COMPOUND\": [\"GRT\", \"FRE\"]\n\n\"ETHNIC GROUP\": []\n\nNote: I assumed \"GRT\" and \"FRE\" are compounds, but if they refer to specific ethnic groups, please let me know.", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about ethnic groups related to the mentioned entities (GRT, ASP, CYP3A4, IC, CYP2C9, or drugs).", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in this sentence)", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" \"ETHNIC GROUP\": []\n\nThese entities are not related to ethnic groups. They are pharmacological inhibitors.", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about any specific ethnic group related to rooibos or the drugs metabolized by CYP2C8 and CYP3A4.", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" \"ETHNIC GROUP\": []", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" No ethnic group information provided in the text.", {"Herb name": ["Echinacea"]}]], [94, "2).", [" It is unclear what \"2.\" refers to in the context of the provided information. There is no mention of any specific entity or ethnic group in the given text.", {}]], [95, "This result was statistically not significant.", [" No ethnic group information provided.", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text regarding E. purpurea)", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific ethnic group reference.", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" \"ETHNIC GROUP\": [\"Not applicable\"]\n\n\"NCI CTCAE\": [\"National Cancer Institute Common Terminology Criteria for Adverse Events\"]", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" No ethnic group information provided in this sentence.", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" No ethnic group information provided in the text.", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" No specific ethnic group mentioned in the text.", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" No ethnic group information provided in the text.", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this case, no specific ethnic group is mentioned in the text.", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"ETHNIC GROUP\": [\"European\"] (assuming E. purpurea refers to European St. John's Wort)", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" No ethnic group information found in this statement.", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about specific ethnic groups related to E. purpurea (European willowherb). The information provided is about the variation in alkylamide content and DTAI distribution across different parts of the plant.", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this context, no specific ethnic group is mentioned.", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this context, no specific ethnic group is mentioned.", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in this context)", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"ETHNIC GROUP\": []", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: Green tea is a beverage and does not have an ethnic group association.)", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" No specific ethnic group mentioned in the text.", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" No ethnic groups mentioned in the text.", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any reference to an ethnic group.", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in this text.)", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"ETHNIC GROUP\": [\"Not specified in text\"]", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {}", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" No ethnic group information provided.", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this text, there is no explicit mention of an ethnic group. The information provided pertains to pharmacokinetic studies and the use of digoxin and GTC (Grapeseed tea catechins).", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"ETHNIC GROUP\": []\n\nThis passage does not provide any information about ethnic groups.", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" \"ENTITY\": [\"GTC (Gynosperma tridifolium)\", \"digoxin\"]\n\n\"GTC (Gynosperma tridifolium)\": []\n\n\"digoxin\": []\n\n\"ETHNIC GROUP\": []\n\n\"This study\": []\n\n\"reduced the systemic exposure\": []\n\n\"coadministration of GTC\": []", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" This passage does not contain any specific ethnic group references. Therefore, the \"ETHNIC GROUP\" field should be left empty.", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" No ethnic group information provided in the text.", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" \"ETHNIC GROUP\": [\"Rats\"]", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" No ethnic group information provided in this text.", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" \"ETHNIC GROUP\": [\"European\"] (Assuming the context is referring to the European Pharmacopoeia or European researchers)", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group. It is discussing nuclear receptors, which are found in all organisms.", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"ETHNIC GROUP\": [\"European\", \"Asian\"] (Assuming the studies referenced were conducted on a diverse population)", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" \"ETHNIC GROUP\": [\"European\", \"Asian (Korean)\"]", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis conclusion does not provide any information about ethnic groups.", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" \"ETHNIC GROUP\": [\"Korean\"]", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" No specific ethnic group mentioned in the text.", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" No ethnic group information provided.", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" \"ETHNIC GROUP\": [\"European\"] # Assuming the authors are European in this context.", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"ETHNIC GROUP\": [\"\"]", {}]], [137, "Contents of ginsenosides in RGE.", [" \"ETHNIC GROUP\": [\"European\"]\n\n\"ENTITY\": [\"ginsenosides\", \"RGE\"]\n\n\"TYPE\": [\"content\"]", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" This citation does not provide any information about ethnic groups.", {}]], [139, "2014; Dybro et\u00a0al.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis information does not provide any details about ethnic groups.", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" No entities found in this sentence.", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" No ethnic group information provided in this text.", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" No ethnic group information provided in the text.", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text)", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" No ethnic group information provided.", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" No ethnic group information provided.", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" \"ETHNIC GROUP\": [\"Rats\"]", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" No ethnic group information provided.", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" No ethnic group information provided in the text.", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" No specific ethnic group mentioned in the text.", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" {}", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis statement does not refer to any specific ethnic group. It is discussing reports and studies related to combinations of Traditional/Herbal Medicine with Western drugs.", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" \"ETHNIC GROUP\": []", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" I cannot directly parse the literature for you, but based on the context provided, it seems that the literature being referred to is related to Traditional Chinese Medicine (TCM) and its interaction with digoxin. Therefore, no specific ethnic groups are mentioned in this context.\n\nRegarding the mechanism of interaction between TCM formulations and digoxin, it is mentioned that there are multiple possible interactions, including:\n\n1. Increased absorption of digoxin due to the inhibition of P-glycoprotein (P-gp) by certain TCM components.\n2. Increased distribution of digoxin to peripheral tissues due to the inhibition of multidrug resistance-associated proteins (MRP) by certain TCM components.\n3. Increased metabolism of digoxin due to the induction of cytochrome P450 enzymes by certain TCM components.\n4. Altered renal clearance of digoxin due to the inhibition of organic cation transporters (OCT) by certain TCM components.\n\nTherefore, the mechanism of interaction between TCM formulations and digoxin is not directly related to any specific ethnic group.", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"ETHNIC GROUP\": [\"African\", \"Asian\"]\n\n\"Chuanxiong\": [\"Chinese\"]\n\"Biantaobanjiuju\": [\"African\"]\n\"Tapinanthus sessilifolius\": [\"Unknown\"]\n\"Mugua\": [\"Chinese\"]\n\"Yinxing\": [\"Chinese\"]", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" \"ETHNIC GROUP\": [\"Mice\"]", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" \"ETHNIC GROUP\": [\"Li\", \"Xin\", \"et al.\"]", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"ETHNIC GROUP\": [\"Chinese\"]\n\nEntities:\n- C. pinnatifida Bunge (Shanzha)\n- digoxin\n- rats\n- flavonoid glycoside\n- flavane polymers\n- ventricular arrhythmias\n- QRS interval\n- ventricular precontraction\n- ventricular tachycardia\n- ventricular fibrillation\n- blood vessels\n- blood pressure\n- heart rhythm\n- cardiovascular system.", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" \"ETHNIC GROUP\": [\"Chinese\"]\n\nNote: The term \"qi, blood, yin and yang\" refers to traditional Chinese medical concepts.", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" \"ETHNIC GROUP\": [\"Chinese\"]\n\n\"TCM\": [\"Traditional Chinese Medicine\"]", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group was mentioned in the context of Traditional Chinese Medicine formulations being complex.)", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" \"ETHNIC GROUP\": [\"Chinese\"]\n\n\"TCM formulations\": [\"Traditional Chinese Medicine\"]", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" No specific ethnic group mentioned in the text.", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" \"ETHNIC GROUP\": [\"Human\"]", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" No specific ethnic group mentioned in the text.", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" \"ETHNIC GROUP\": []", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in the provided text)", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"ETHNIC GROUP\": [\"Asian\"]", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" \"ETHNIC GROUP\": [\"N/A\"]\n\nThis passage does not mention any specific ethnic group.", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"ETHNIC GROUP\": []\n\nDMSO is an organic compound, not an ethnic group.", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" No ethnic group information provided.", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" \"ETHNIC GROUP\": []\n\nThis passage does not contain any specific ethnic group references.", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" No ethnic group information provided.", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" No ethnic group mentioned in the text.", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" I'm unable to determine the context of the reference \"2 above\" without additional information. Therefore, I cannot parse any entities from it.", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" No ethnic group information provided.", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" This line does not contain any information about ethnic groups. It is just a reference to a figure object name.", {}]], [177, "Mean\tS.D.", [" \"MEASUREMENT UNIT\": [\"Mean\", \"Standard Deviation\"]\n\nThis information does not refer to any specific entities, so no ethnic groups need to be identified.", {}]], [178, "Mean\tS.D.", [" \"MEASUREMENT UNIT\": [\"Mean\", \"Standard Deviation\"]\n\nThis information does not refer to any specific entities, so no ethnic groups need to be identified.", {}]], [179, "***P < 0.0001.", [" This is a statistical term and does not refer to an ethnic group.", {}]], [180, "; data not shown).", [" {}", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" This passage does not contain any specific ethnic group references.", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" No ethnic groups mentioned in the text.", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or identify entities related to an external file as I don't have the ability to access or process external data. However, if the text mentions a specific file name or type of file, I can identify that information. For example:\n\n{\"FILE\": [\"filename.jpg\", \"file.pdf\"]}\n\nIn the given context, there is no mention of a specific file name or type.", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" This line does not contain any information about ethnic groups. It is just a reference to a figure object name.", {}]], [185, "Data shown are the means \u00b1 S.D.", [" No ethnic group information provided in this statement.", {}]], [186, "of triplicate determinations.", [" Empty. This term does not refer to an ethnic group.", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" \"ETHNIC GROUP\": [\"Human\"]", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" No specific ethnic group mentioned in the text.", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" No specific ethnic group mentioned in the text.", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in this context)", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" No specific ethnic group mentioned in the text.", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in the provided text)", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" \"ETHNIC GROUP\": [\"American\"] (Agilent is a company based in the United States)", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" No ethnic group information provided.", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" \"ETHNIC GROUP\": []", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" No ethnic group information provided.", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"ETHNIC GROUP\": [\"Rats\"]", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" No ethnic group information provided.", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was provided in the text regarding 'berberine'.", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" No specific ethnic group mentioned in the text.", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis text does not provide any information about ethnic groups.", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" \"ETHNIC GROUP\": [\"N/A\"]\n\nNo specific ethnic group information was mentioned in the text.", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" No specific ethnic group mentioned in the text.", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" \"ETHNIC GROUP\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" I assume you meant to add \"initials\" or \"names\" to the list, here's the updated format:\n\n{\"ETHNIC GROUP\": [\"African\", \"Southern African\"], \"PERSON\": [\"Cassia abbreviata is a medium-sized tree that grows in most parts of Africa, especially utilized in Southern African countries such as Botswana, South Africa, Uganda, Zambia, and Zimbabwe. [M.P.]\"}", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" No ethnic group information provided.", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" No specific ethnic group mentioned in this text.", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" No specific ethnic group mentioned in the text.", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"ETHNIC GROUP\": []\n\nThis information does not specify an ethnic group. It is discussing the side effects of the drugs EFV and NVP.", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" \"ETHNIC GROUP\": [\"Developing countries\"]", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" \"ETHNIC GROUP\": []", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"ETHNIC GROUP\": [\"\"]\n\nThis information does not specify an ethnic group. It is discussing genetic polymorphism in the CYP2B6 enzyme, which is a human gene and not specific to any ethnic group.", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" No specific ethnic group mentioned in the text.", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" {\"ETHNIC GROUP\": []}\n\nThis passage does not mention any specific ethnic group.", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" No specific ethnic group mentioned in the text.", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about the ethnic group related to the mentioned plant extracts (Launaea taraxacifolia, Hyptis suaveolens, Boerhavia diffusa, and Myrothamnus flabellifolius).", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" \"ETHNIC GROUP\": [\"South African\"]", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" No specific ethnic group mentioned in the text.", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" \"ETHNIC GROUP\": [\"Denis Chopera\", \"Kevin Dzobo\", \"Ambroise Wonkam\", \"Dee Blackhurst\", \"Michelle Skelton\"] (Assuming these are individual names)", {}]], [220, "All authors reviewed the final manuscript.", [" \"ETHNIC GROUP\": []", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" \"DRUGS\": [\"GGT\", \"five major ingredients\"]\n\n\"ETHNIC GROUP\": []\n\nNote: I assumed \"GGT\" refers to a specific drug or medication, but without more context it's impossible to determine if it has an ethnic association.", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" No ethnic group information provided in this text.", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" No ethnic group information provided in this statement.", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" No specific ethnic group mentioned in the text.", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" No specific ethnic group mentioned in the text.\n\n{\"ETHNIC GROUP\": []}", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group.", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" I'm unable to determine an ethnic group based on the abbreviation \"Y.C.P.\" without additional context.", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" It is unclear what \"performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.\" refers to in this context. No ethnic groups can be identified from this information.", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis information does not provide any details about ethnic groups.", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" \"ETHNIC GROUP\": [\"Elderly\"]\n\n\"PLANTS\": [\"St. John\u2019s wort\", \"Garlic oil\", \"Panax ginseng\", \"Ginkgo biloba\"]", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"ETHNIC GROUP\": [\"Patients taking prescription medications\", \"Individuals greater than 65 years of age\"]", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"ETHNIC GROUP\": [\"Elderly\"]", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" No ethnic group information provided in this statement.", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" No ethnic group mentioned in the text.", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text)", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" This information does not provide any specific ethnic group references. Therefore, there is no need to include an entry for \"ETHNIC GROUP\" in this case.", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" \"ETHNIC GROUP\": [\"Not specified in the text\"]", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" No ethnic group information provided in the text.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" No ethnic group information provided.", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"ETHNIC GROUP\": []", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" \"ETHNIC GROUP\": [\"Elderly\"]", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" \"ETHNIC GROUP\": []\n\nThis statement does not mention any specific ethnic group. It refers to the compound \"ginkgolides,\" which are derived from the Ginkgo biloba tree.", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" No ethnic group information provided in this citation.", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" \"ETHNIC GROUP\": [\"European\", \"Asian\"] (for Panax ginseng)", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"ETHNIC GROUP\": [\"European\"]\n\n\"Biotransformation\": [\"metabolic process\"]\n\n\"Warfarin\": []\n\n\"CYP2C9\": []\n\n\"S-warfarin\": []\n\n\"Ginseng\": []\n\n\"Enzyme induction\": []", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" No specific ethnic group mentioned in the text.", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any details about ethnic groups.", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" \"ETHNIC GROUP\": [\"Not applicable\"]\n\nThe text does not provide information about any specific ethnic group.", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was provided in this text.", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" No ethnic group mentioned in the text.", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"ETHNIC GROUP\": [\"\"]\n\nNo ethnic group information was provided in the text.", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this text, there is no explicit mention of an ethnic group.", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" No ethnic group information provided in the text.", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" No ethnic group information provided.", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" No ethnic group information provided in this sentence.", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"ETHNIC GROUP\": [\"Not specified in the text\"]\n\nThe text does not provide information about any specific ethnic group related to the mentioned plants or studies.", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group.", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" No ethnic groups mentioned in this statement.", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any details about ethnic groups.", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"ETHNIC GROUP\": [\"Adults in KwaZulu-Natal\"]\n\n\"ETHNIC GROUP\": [\"HIV positive individuals\"]\n\n\"ETHNIC GROUP\": [\"Worldwide\"]", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" No specific ethnic group information is provided in this statement.", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" No ethnic groups mentioned in the text.", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" {\"ETHNIC GROUP\": []}\n\nThese abbreviations do not refer to any specific ethnic group.", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" This line does not contain any information about ethnic groups.", {}]], [265, "Thabethe, D.A.", [" {\"PERSON\": [\"Thabethe, D.A.\"]}}", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" No ethnic group information provided in this sentence.", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" \"ETHNIC GROUP\": []\n\n\"CKD\": [\"chronic kidney disease\"]\n\nNote: No ethnic group was mentioned in the text.", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" No specific ethnic group mentioned in the text.", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" \"ETHNIC GROUP\": [\"Not specified in the text\"]", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" {\"ETHNIC GROUP\": [\"\"]}\n\nThis information does not provide any specific ethnic group information.", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" \"ETHNIC GROUP\": []", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" {}", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" No specific ethnic group mentioned in the text.", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"ETHNIC GROUP\": [\"Iranian\"]", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" No ethnic group information was provided in the given reference [27].", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" \"ETHNIC GROUP\": []\n\nThis text does not provide any information about ethnic groups.", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" \"ETHNIC GROUP\": []\n\nThis sentence does not provide any information about ethnic groups.", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" No specific ethnic group mentioned in this text.", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" No specific ethnic group mentioned in the text.", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"INTERNATIONAL NORMRIZED RATIO\": []\n\n\"ETHNIC GROUP\": []\n\n(Note: INR is a laboratory value and does not refer to an ethnic group)", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" No specific ethnic group mentioned in the text.", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" No ethnic groups mentioned in the text.", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" No specific ethnic group mentioned in the text.", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" No ethnic group information provided in this statement.", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"ETHNIC GROUP\": [\"European\"] or [\"N/A\"] (as the text does not provide specific information about the ethnic groups related to the conducted study or the sources of the data in the table)", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" \"ETHNIC GROUP\": []", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" \"ETHNIC GROUP\": [\"\"]\n\n(This passage does not mention any specific ethnic group)", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" reported 11 patients with atrial fibrillation in (2006a)\n\n\"ETHNIC GROUP\": [] # No ethnic group information provided in the text.", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis passage does not mention any specific ethnic group.", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" \"ETHNIC GROUP\": [\"N/A\"]\n\nThe text does not provide information about ethnic groups related to the entities mentioned.", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThere is no specific ethnic group mentioned in the text.", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"ETHNIC GROUP\": [\"European\"]\n\"VALERIAN\": [\"Valeriana officinalis\"]\n\nNote: CYP 3A4 is a metabolic enzyme, not an ethnic group.", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" No specific ethnic group mentioned in this context.", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was provided in the text.", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" \"ETHNIC GROUP\": [\"German\"]", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" No specific ethnic group mentioned in the text.", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" No ethnic group information provided in this text.", {}]], [298, "[36].", [" It is unclear what entity is referred to in reference [36]. Therefore, no information can be provided for this field.\n\n{\"ETHNIC GROUP\": []}", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was provided in the text.", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" \"ETHNIC GROUP\": [\"Not specified in text\"]", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" \"ETHNIC GROUP\": []\n\n(The text does not provide any information about the ethnic group related to the given information.)", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" No specific ethnic group mentioned in this statement.", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text)", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" \"ETHNIC GROUP\": [\"\"]}\n\nIn this context, no specific ethnic group is mentioned in relation to the herbal medicines or the valerian preparation.", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" No specific ethnic group mentioned in the text.", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" No specific ethnic group mentioned in the text.", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" No ethnic group mentioned in the text.", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" \"ETHNIC GROUP\": [\"European\"] (Regarding the context of the text, it refers to the European Medicines Agency (EMA) or European Medicines Agency's Committee on Herbal Medicinal Products (HMPC) and the Office of Dietary Supplements at the National Institutes of Health (NIH) in the United States.)", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis information does not provide any specific ethnic group information.", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" No ethnic group information provided in this text.", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" No ethnic group information provided in this statement.", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group information was provided in this context.)", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" {}", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" No specific ethnic group mentioned in the text.", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" \"ETHNIC GROUP\": []", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" {\"ETHNIC GROUP\": []}", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" \"ETHNIC GROUP\": [\"Brasilian Portuguese\"]\n\nThis is a Portuguese text which translates to \"A wide investigation was conducted, including LBA, imaging studies, autoimmune disease detection, right heart catheterization, and myocardial biopsy.\" Since no specific ethnic group is mentioned in the text, the output remains the same as the input.", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" \"ETHNIC GROUP\": [\"\"]\n\nExplanation: The text does not provide information about ethnic groups related to the mentioned entities.", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" \"ETHNIC GROUP\": [\"\"]\n\n(This text is in Portuguese and it refers to renal and hepatic parameters, complement proteins, and urinary sediment, which do not specify any ethnic group.)", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: The text does not provide information about ethnic groups related to the mentioned topic of cardiac medicines being discontinued.)", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis text does not provide any information about ethnic groups.", {}]], [323, "Apoio financeiro: Nenhum.", [" This text does not provide any information related to ethnic groups.", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in the provided context)", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"ETHNIC GROUP\": [\"Women\"]\n\nExclusion criteria related to medical conditions:\n1. women who became menopausal from surgery or chemotherapy\n2. women who underwent hysterectomy\n3. women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers\n4. women with uncontrolled hypertension (160/100 mmHg or higher)\n5. women with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo)\n6. uncontrolled thyroid patients\n7. women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease\n8. women with atypical uterine bleeding after 1 yr of menopause\n9. women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk\n10. women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk\n11. women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk\n12) women who were administered female hormone formulations within 6 mo\n13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit\n14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit\n15) women with a history of drug or alcohol abuse\n16) women who have performed intensive", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" No ethnic group information was provided in this statement.", {}]], [328, "p-value by Fisher's exact test.", [" \"p-value\": [\"\"]\n\n\"STATISTICAL TEST\": [\"Fisher's exact test\"]", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" \"ETHNIC GROUP\": []", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" No ethnic group information provided in this statement.", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" {}", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" \"ETHNIC GROUP\": []\n\nThis passage does not contain any specific reference to ethnic groups.", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" No specific ethnic group mentioned in the text.", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" This statement does not refer to any specific ethnic group. It is a general statement about enzyme kinetics.", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {\"CHEMICAL COMPOUND\": [\"celastrol\"]}\n\n\"ETHNIC GROUP\": []", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"ETHNIC GROUP\": [\"Human\"]", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" \"DRUGS\": [\"clofibric acid\", \"valproic acid\"]}\n\n\"ETHNIC GROUP\": []}\n\nPlease note that \"ETHNIC GROUP\" field should only contain information about ethnic groups and not countries in general.", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" \"ETHNIC GROUP\": []", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" \"ETHNIC GROUP\": []\n\nThis sentence does not provide any information about ethnic groups. It is about the inhibition kinetic analysis of celastrol towards UGT2B7-catalyzed 4-MU glucuronidation.", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" \"ETHNIC GROUP\": [\"\"]\n\nThere is no explicit mention of an ethnic group in this context. The information provided pertains to the therapeutic benefits of ginseng.", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"ETHNIC GROUP\": [\"European\"] (Assuming the study was conducted in Europe)", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group was mentioned in the text related to this information.)", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"ETHNIC GROUP\": []\n\nThis passage does not contain any specific ethnic group references.", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"ETHNIC GROUP\": [\"Rat\"]", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in this text.)", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" No ethnic group information provided in the text.", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" No ethnic group information provided in the text.", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" \"ETHNIC GROUP\": [\"Rats\"]", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"ETHNIC GROUP\": [\"\"]\n\nThis statement does not refer to any specific ethnic group. It is a general statement about herbal products and their assessment for efficacy, safety, and potential interactions with other drugs.", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" No ethnic group information provided.", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" No ethnic group information provided in the text.", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: PCOS is a medical condition and not an ethnic group)", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group. It is discussing the use of herbal agents to treat Polycystic Ovary Syndrome (PCOS) as a disease of antioxidant deficiency.", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" No ethnic group information provided in this sentence.", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about any specific ethnic group related to Citrus Sinensis or Rutaceae family.", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" \"ETHNIC GROUP\": [\"Chinese\"]\n\n\"SPECIES\": [\"Citrus sinensis\"]\n\n\"COMPOUNDS\": [\"Hesperidin\", \"SOD (Superoxide dismutase)\", \"CAT (Catalase)\", \"MDA (Malondialdehyde)\"]", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" \"ETHNIC GROUP\": []\n\nThe text does not provide any information about ethnic groups.", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was provided in the text.", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" No specific ethnic group mentioned in this text.", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" \"ETHNIC GROUP\": []", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" No ethnic groups mentioned in this text.", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group. It is a general statement about medicinal plants and their antioxidant activity.", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" No specific ethnic group mentioned in this statement.", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"ETHNIC GROUP\": []\n\nThis sentence does not provide any information about ethnic groups. It is discussing the mechanism by which ginger decreases FBS (Fasting Blood Sugar) levels.", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" \"ETHNIC GROUP\": []", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" \"ETHNIC GROUP\": []", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" \"ETHNIC GROUP\": [\"Women with Polycystic Ovary Syndrome (PCOS)\"]", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" {}", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" No specific ethnic group mentioned in the text.", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" \"ETHNIC GROUP\": [\"\"]}\n\nIn this text, there is no explicit mention of an ethnic group.", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" No ethnic group information found in this text.", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" \"ETHNIC GROUP\": [\"Not specified in text\"]", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" No specific ethnic group mentioned in the text.", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" No ethnic group information provided in this sentence.", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" No ethnic group information provided in this text.", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" \"DRUG NAME\": [\"Darunavir\"]", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"ETHNIC GROUP\": [\"\"]\n\n(In this context, no specific ethnic group is mentioned in the text.)", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this text, there is no explicit mention of an ethnic group related to the described entities.", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" \"ETHNIC GROUP\": [\"\"]\n\nThere is no specific ethnic group mentioned in this context.", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group. It is discussing the variability in the effect of echinacea on darunavir pharmacokinetics in a general context.", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in this context)", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" No ethnic group information provided in this text.", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" \"ETHNIC GROUP\": []", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this passage, no specific ethnic group is mentioned.", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" No ethnic groups found in this statement.", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" No ethnic groups mentioned in the text.", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" \"EGb 761\u00ae\": []\n\nThis term does not refer to an ethnic group. It is likely a reference to a specific herbal medication.", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" \"ETHNIC GROUP\": []\n\nThis passage does not contain any specific reference to an ethnic group.", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in the provided context)", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" No ethnic group information provided in this statement.", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {}", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {}", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" This statement does not contain any specific entities or ethnic groups.", {}]], [395, "Type of participant.", [" It is not clear from the provided text which ethnic group the participants in the study are.", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis statement does not refer to any specific ethnic group. An herb is a product or an extract originating from a single botanical source, regardless of the ethnic group of the researchers or the location where the herb is grown.", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" \"ETHNIC GROUP\": []", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" I cannot directly provide the ethnic group information from the given text as it does not mention any specific ethnic group related to the table or the herbal preparations.", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" \"ETHNIC GROUP\": []\n\nThis passage does not provide any information about ethnic groups. It only mentions the number of trials and their references.", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" This information does not refer to any specific ethnic group.", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"ETHNIC GROUP\": [\"Not applicable\"]", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" \"ETHNIC GROUP\": []", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" No specific ethnic group mentioned in this statement.", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" No specific ethnic group mentioned in the text.", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" \"ETHNIC GROUP\": []\n\nThis sentence does not provide any information about ethnic groups. It is about an in vivo study related to the herb Echinacea and its effect on drug metabolism.", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text.)", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" {}", {}]], [408, "(DOCX) Click here for additional data file.", [" This text does not provide any information about entities related to ethnic groups.", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: Warfarin is a drug and does not refer to an ethnic group)", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any details about the ethnic group of the person mentioned in the text.", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" \"ETHNIC GROUP\": [\"\"]}\n\nThe text does not provide information about ethnic groups related to the mentioned diagnostic considerations.", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" \"ETHNIC GROUP\": [\"Not specified in text\"]", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" No ethnic group information provided.", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" No specific ethnic group mentioned in the text.", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" No specific ethnic group mentioned in the text.", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis limitation is related to predicting herb-drug interactions, and it does not specifically refer to any ethnic group.", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" \"ETHNIC GROUP\": [\"Human\"]", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis passage does not refer to any specific ethnic group.", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" No specific ethnic group mentioned in the text.", {}]], [420, "Supporting Information Click here for additional data file.", [" I cannot access or parse the information from a link or a data file. The provided text should be sufficient for identifying the cited entities.", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" \"ETHNIC GROUP\": [\"American\"]", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" \"CURCUMIN\": [\"curcumin\"]\n\"ETHNIC GROUP\": []\n\nThere is no mention of any specific ethnic group in this part of the text.", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" No specific ethnic group mentioned in the text.", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" \"ETHNIC GROUP\": [\"Traditional Chinese\"]", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group. It is discussing the pharmacokinetic properties of carbamazepine (CBZ) and its potential interactions with other substances.", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" No specific ethnic group mentioned in the text.", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" \"ETHNIC GROUP\": [\"\"]}\n\n[These citations do not provide enough information to determine an ethnic group.]", {}]], [428, "2012).", [" {}", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" \"ETHNIC GROUP\": [\"Human\"]", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"ETHNIC GROUP\": [\"Rats\", \"Children\"]", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" \"ETHNIC GROUP\": []", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" No ethnic group information provided in the text.", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about ethnic groups related to the Chinese databases.", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about ethnic groups related to Ispaghula husk, septilin, soybean, or Xiao-cha-hu-tang.", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" No ethnic group mentioned in the text.", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group was mentioned in the text.)", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" This term does not refer to any specific ethnic group.", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" \"ETHNIC GROUP\": [\"Not specified\"]", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" \"ETHNIC GROUP\": [\"All\"]", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" No ethnic group information provided in the text.", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" No specific ethnic group information is provided in the given text.\n\n{\"ETHNIC GROUP\": []}", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" No specific ethnic group mentioned in this statement.", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" This information does not provide any specific ethnic group references.", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"ETHNIC GROUP\": []", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis passage does not provide any specific information about ethnic groups. It is discussing healthcare practitioners in general.", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Herb-drug interactions are a general concept and do not refer to a specific ethnic group.)", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group was mentioned in the text)", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"ETHNIC GROUP\": []\n\n(Note: HepaRG cell line is derived from a human hepatocellular carcinoma, it does not refer to any specific ethnic group.)", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" No ethnic group mentioned in the text.", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" No ethnic group information provided in the text.", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" No entities found in this sentence.", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" \"ETHNIC GROUP\": [\"Human\"]", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" \"ETHNIC GROUP\": [\"N/A\"]\n\nThis passage does not contain any specific reference to an ethnic group.", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No ethnic group information was provided in the text.)", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group.", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" No ethnic group information provided.", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" No specific ethnic group information in this statement.", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" No specific ethnic group mentioned in this statement.", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" No specific ethnic group mentioned in the text.\n\n{\"ETHNIC GROUP\": []}", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" \"ETHNIC GROUP\": []", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about the ethnic group related to CYP3A4, Samento, or Banderol.", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this passage, no specific ethnic group is mentioned.", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" No specific ethnic group mentioned in the text.", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"ETHNIC GROUP\": [\"European\"] # St. John\u2019s Wort is an herbal preparation\n\n\"DRUGS\": [\"rifampicin\", \"St. John\u2019s Wort\"]", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" \"ETHNIC GROUP\": []\n\nThis passage does not contain any specific reference to an ethnic group.", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" \"ETHNIC GROUP\": [\"Not applicable\"]", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" No ethnic group information provided in the text.", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" No specific ethnic group mentioned in the text.", {}]], [471, "Data were evaluated as described previously [28].", [" No specific ethnic group mentioned in the text.", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" No specific ethnic group mentioned in the text.", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" \"ETHNIC GROUP\": []", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" This information does not refer to any specific ethnic group.", {}]], [475, "Results of the reporter gene assays.", [" No ethnic group information provided.", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" \"PXR\": []\n\n\"Samento\": []\n\n\"rifampicin\": []\n\n\"concentration-dependent effect\": []\n\n\"activity\": []\n\n\"pregnane x receptor\": []\n\n\"positive control\": []\n\n\"insert\": []\n\n\"effect on\": []\n\n\"pregnane x receptor (PXR) activity\": []\n\n\"Samento and\": []\n\n\"rifampicin on\": []\n\n\"pregnane x receptor (PXR) activity\": []\n\n\"concentration-dependent\": []\n\n\"position\": [\"insert\"]\n\n\"effect\": [\"Samento and pregnane x receptor (PXR) activity\", \"rifampicin and pregnane x receptor (PXR) activity\"]\n\n\"position and effect\": [\"insert and effect on pregnane x receptor (PXR) activity\"]\n\n\"substance\": [\"Samento\", \"rifampicin\"]\n\n\"phenomenon\": [\"concentration-dependent effect\"]\n\n\"target\": [\"pregnane x receptor (PXR)\"]\n\n\"action\": [\"effect on pregnane x receptor (PXR) activity\"]\n\n\"comparison\": [\"positive control\"]\n\n\"position and comparison\": [\"insert and positive control\"]\n\n\"position\": [\"position\"]\n\n\"substance and position\": [\"Samento and position\", \"rifampicin and position\"]\n\n\"substance and comparison\": [\"Samento and positive control\", \"rifampicin and positive control\"]\n\n\"phenomenon and comparison\": [\"concentration-dependent effect and positive control\"]\n\n\"target and comparison\": [\"pregnane x receptor (PXR) and positive control\"]\n\n\"action and comparison\": [\"effect on pregnane x receptor (PXR) activity and positive control\"]\n\n\"substance and target and action\": [\"Samento, pregnane x receptor (PXR), and effect on pregnane x receptor (PXR) activity\"]\n\n\"substance and target\": [\"Samento, pregnane x receptor (PXR)\"]\n\n\"substance and action\": [\"Samento, effect on pregnane x receptor (PXR) activity\"]\n\n\"target and action\": [\"", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about any specific ethnic group related to Samento or rifampicin.", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text regarding the entity \"LS180 cells\")", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" \"ETHNIC GROUP\": []", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group information was provided in the text regarding the mentioned drugs.)", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" No ethnic group information provided.", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" \"ETHNIC GROUP\": [\"Korean\"]", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"ETHNIC GROUP\": [\"Korean\"]\n\nThe following entities were identified in the text:\n\n* Bovis Calculus\n* Dioscoreae Rhizoma\n* Glycyrrhizae Radix et Rhizoma\n* Ginseng Radix\n* Typhae Pollen\n* Massa Medicata Fermentata\n* Glycine Semen Germinatum\n* Cinnamomi cortex\n* Paeoniae Radix\n* Liriopis Tuber\n* Scutellariae Radix\n* Angelicae Gigantis Radix\n* Saposhnikoviae Radix\n* Atractylodis Rhizoma Alba\n* Bupleuri Radix\n* Platycodonis Radix\n* Armeniacae Semen\n* Poria Sclerotium\n* Cnidii Rhizoma\n* Civet\n* Antelopis Cornu\n* Borneolum\n* Ampelopsis Radix\n* Zingiberis Rhizoma\n\nThe text mentions that the suspension is produced by the Kwang-Dong Pharmaceutical Company in Seoul, Korea. Therefore, the ethnic group associated with this information is \"Korean\".", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" No ethnic group information provided in this statement.", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" \"ETHNIC GROUP\": [\"Not specified in text\"]", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" \"ETHNIC GROUP\": []", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" No ethnic group information provided.", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" No ethnic group information provided.", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" No specific ethnic group mentioned in the text.", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" No specific ethnic group mentioned in the text.", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" No ethnic group information provided in this statement.", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" \"ETHNIC GROUP\": []\n\nThis part of the text does not provide any information about ethnic groups.", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" \"ETHNIC GROUP\": []\n\nThis statement does not mention any specific ethnic group. It is discussing the interaction between certain fruits (grapefruit and pomegranate) and specific types of statins.", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group. It is a general statement about malignancies and tyrosine kinases.", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"ETHNIC GROUP\": []\n\nThis passage does not contain any specific ethnic group references.", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" No ethnic group information provided in the text.", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group.", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" \"DRUG\": [\"drug-metabolizing enzymes\", \"drug transporters\"]\n\"ETHNIC GROUP\": [\"\"]\n\nNote: No specific ethnic group was mentioned in the text.", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" No ethnic group information provided in this text.", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" No specific ethnic group mentioned in the text.", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" \"ETHNIC GROUP\": [\"Animals\"]", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" No ethnic groups mentioned in this text.", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" \"ETHNIC GROUP\": []\n\nThis passage does not contain any specific reference to an ethnic group.", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" No ethnic group information provided.", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" \"ETHNIC GROUP\": [\"Humans\"]", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" I cannot determine an ethnic group based on the given abbreviation \"M.A.A.\". Please provide more context or clarify the abbreviation for accurate identification.", {}]], [507, "; supervision, K.M.A.", [" {\"ETHNIC GROUP\": []}", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" This statement does not refer to any specific ethnic group.", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" \"ETHNIC GROUP\": [\"Saudi Arabian\"]", {}]], [510, "All results are presented as the average \u00b1 SD.", [" No ethnic group information provided in this statement.", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" \"ETHNIC GROUP\": [\"Rats\"]", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group. It is a general statement about the field of phytochemistry and drug interactions.", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" \"ETHNIC GROUP\": [\"Population\"]\n\nThis statement does not specify a particular ethnic group. The term \"population\" is used to refer to the group of people being discussed in a broader sense.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" No specific ethnic group mentioned in the text.", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" No ethnic group information provided in the text.", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" No ethnic groups mentioned in the text.", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {}", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" No ethnic groups mentioned in the text.\n\n{\"ETHNIC GROUP\": []}", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" No ethnic group information provided in this text.", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" No ethnic group information provided in this sentence.", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" No ethnic group information provided in the text.", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" No ethnic group information provided in this statement.", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" No ethnic group information provided in the text.", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" No specific ethnic group mentioned in the text.", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"ETHNIC GROUP\": [\"European\"] (St. John's wort is a herbal medicine commonly used in Europe)", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" \"ETHNIC GROUP\": []", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" \"ETHNIC GROUP\": []", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" \"ETHNIC GROUP\": []\n\nNo specific ethnic group information was provided in the text.", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"ETHNIC GROUP\": [\"European\", \"Asian\"] (Assuming the investigators mentioned are of various ethnic backgrounds)", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"ETHNIC GROUP\": []", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"ETHNIC GROUP\": [\"German\"]\n\nReferences: [12], [154], [24]\n\n[12]: European Union\n[24]: Zhang\n[154]: European Pharmacopoeia", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" \"ETHNIC GROUP\": [\"European\"] (Assuming Zahner et al. are European)", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis passage does not provide any specific information about ethnic groups. It only mentions the use of pharmacoepidemiology methods and bioinformatics in identifying clinical meaningful herb-drug interactions in cancer therapies.", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" \"ETHNIC GROUP\": [\"Chinese\"]\n\n\"ENTITIES\": [\"Lingzhi\", \"Yunzhi\"]", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" No specific ethnic group mentioned in this statement.", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {}", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"ETHNIC GROUP\": [\"Not specified in given text\"]\n\nThe text does not provide information about specific ethnic groups related to the mentioned entities. The entities mentioned in the text are mainly related to medical research, pharmacology, and biochemistry. Here are the entities and their descriptions:\n\n* T cells: white blood cells that play a crucial role in cell-mediated immunity.\n* Apoptosis: programmed cell death.\n* Caspase 3: a cysteine protease that plays a key role in the execution phase of apoptosis.\n* Bax: a protein that plays a role in the initiation of apoptosis.\n* WBC (White Blood Cells): a type of immune cell that helps fight infections.\n* CD3+, CD4+ T cells: specific types of T cells that play different roles in the immune system.\n* NK cells: natural killer cells, a type of white blood cell that helps fight infections.\n* Platelets: small disc-shaped cell fragments that play a crucial role in blood clotting.\n* 5-FU: a chemotherapeutic drug used to treat various types of cancer.\n* Cytotoxic drugs: drugs that damage or destroy cells, often used in cancer treatment.\n* Medicinal mushrooms: various species of mushrooms used for medicinal purposes.\n* Phagocytic activity: the ability of certain white blood cells to engulf and destroy foreign particles.\n* Antibody production: the process by which the immune system produces antibodies to fight infections.\n* Delayed hypersensitivity: a type of immune response characterized by a delayed reaction to an antigen.\n* Immunosuppression: the suppression of the immune system, often used to prevent rejection of transplanted organs.\n* Metastasis: the spread of cancer from one part of the body to another.\n* Cell cycle arrest: the halting of the cell cycle at a specific phase.\n* Caspase 8: a cysteine protease that plays a role in initiating apoptosis.\n* Preclinical studies: research conducted before clinical trials to evaluate the safety and efficacy of a drug or treatment.\n* Survival time: the length of time a patient lives after being diagnosed with a disease.\n", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was provided in the text regarding the mentioned Yunzhi\u2013drug combinations.", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" No specific ethnic group mentioned in this part of the text.", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" No specific ethnic group mentioned in the text.", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about any specific ethnic group related to Yunzhi or the mentioned mechanisms.", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" It is unclear what \"a\" refers to in this context. Please provide more information for proper parsing.", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" {\"ETHNIC GROUP\": []}\n\nThe text does not provide information about specific ethnic groups related to the mentioned mechanisms.", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis passage does not mention any specific ethnic group. The term \"clinical settings\" is a general term and does not refer to a specific ethnic group.", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" It is unclear what entities are referred to in Table S4 as no text is provided with this citation. Therefore, no information can be added for this field.\n\n{\"ETHNIC GROUP\": []}", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" \"ETHNIC GROUP\": []", {}]], [547, "Not applicable.", [" {}", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" \"ETHNIC GROUP\": [\"Women\"]", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific ethnic group information.", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific ethnic group information.", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" \"ETHNIC GROUP\": []\n\nThis passage does not mention any specific ethnic group. It only provides information about the host tree (Malus domestica) of VAEM (Viscum album europaeum mistletoe) and the name of a product (Iscador Qu spec.).", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" \"ETHNIC GROUP\": [\"American\"]", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" \"ETHNIC GROUP\": []\n\nThis text does not contain any explicit mention of ethnic groups.", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" No specific ethnic group mentioned in the text.", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"ETHNIC GROUP\": []\n\nThis statement does not provide any information about ethnic groups. It is discussing the association between CYP2D6 metabolism and breast cancer outcomes.", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"ETHNIC GROUP\": [\"\"]\n\n(It is not possible to determine the ethnicity of the 50 donors from the given information.)", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" No applicable entities found in the given text.", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any reference to an ethnic group.", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" This statement does not refer to any specific ethnic group.", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" \"ETHNIC GROUP\": [\"\"]\n\nThere is no information about an ethnic group related to H. sabdariffa in the provided text.", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" \"ETHNIC GROUP\": []", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" \"BW\": [\"body weight\"]\n\n\"ETHNIC GROUP\": []", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" No ethnic group information provided.", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" {\"ETHNIC GROUP\": [\"\"]}\n\n(No ethnic group information was mentioned in this sentence)", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" No ethnic group information provided in the text.", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" \"ETHNIC GROUP\": [\"Rats\"]", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" \"ETHNIC GROUP\": []", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" No ethnic group information provided.", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" No ethnic group information found in this sentence.", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" \"ETHNIC GROUP\": []", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" This citation does not provide any information about ethnic groups.", {}]], [572, "2016).", [" {}", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" \"ETHNIC GROUP\": [\"Chinese\"]", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" \"ETHNIC GROUP\": [\"American\"]", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" No ethnic group information provided in this text.", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" No specific ethnic group mentioned in the text.", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" Understanding the interaction between Traditional Chinese Medicine (TCM) and modern pharmaceuticals, as described in the article, can have significant implications for clinical pharmacology and translational science. The report of the switching phenomenon between TCM and sildenafil among impotence patients in China highlights the importance of considering the potential drug-drug interactions between TCM and modern pharmaceuticals. This knowledge can help healthcare professionals to better understand the pharmacokinetics and pharmacodynamics of these combinations, optimize dosing regimens, and minimize adverse effects. Additionally, this information can inform the development of more effective and safer therapeutic strategies, particularly in regions where the use of both TCM and modern pharmaceuticals is common. Overall, the integration of TCM into modern healthcare systems requires a deeper understanding of their pharmacological interactions, which can ultimately lead to improved patient outcomes and advancements in translational science.", {}]], [578, "(n\u00a0=\u00a06).", [" This information does not refer to an ethnic group.", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" \"ETHNIC GROUP\": []", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" I cannot extract any ethnic group information from the given initials.", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" It is not possible to determine the ethnicity of the individuals named S.M., Y.O., R.T., J.K., H.W., and M.F. from the provided information.", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" \"ETHNIC GROUP\": [\"Indian\"]", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" No specific ethnic group mentioned in the text.", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"ETHNIC GROUP\": []\n\n\"EJ\": [\"Elderberry juice\"]\n\n\"classes of bioactive constituents\": [\"anthocyanins\", \"flavonoids\"]\n\n\"oral anti-diabetic agents\": [\"Gliptins\"]\n\n\"enzyme\": [\"dipeptidyl peptidase-4 (DDP-4)\"]", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text)", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" \"ETHNIC GROUP\": [\"\"]\n\n(The text does not provide information about any specific ethnic group related to Eugenia jambolana.)", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" No ethnic groups found in this text.", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" No ethnic groups found in this statement.", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in this context)", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" It is unclear what entities are referred to by \"3a and b\". Please provide additional context for proper parsing.", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" No ethnic group information provided.", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" No specific ethnic group mentioned in the text.\n\n{\"ETHNIC GROUP\": []}", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" No ethnic group information provided.", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" This information does not provide any specific ethnic group references.", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" 1] and serum creatinine (Fig. [2]) in the CCl4-treated rats, indicating the protective effect of EJE and EJE\u202f+\u202fSITA against hepatic damage.\n\n\"ETHNIC GROUP\": [] (No ethnic group mentioned in this text)", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" This text does not contain any referenced ethnic groups.", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" This information does not provide any specific ethnic group references.", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide any information about ethnic groups related to A. officinarum or indomethacin.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide any information about ethnic groups related to A. Officinarum or the rats used in the study.", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" No ethnic groups mentioned in the text.\n\n{\"ETHNIC GROUP\": []}", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" \"ETHNIC GROUP\": [\"Rats\"]", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" No ethnic group information provided.", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" No ethnic group information provided.", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" \"ETHNIC GROUP\": [\"N/A\"]\n\nThe text does not provide any information about ethnic groups. The mentioned organization is the U.S. Food and Drug Administration (USFDA).", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" \"ETHNIC GROUP\": [\"\"]}\n\nIn this context, no specific ethnic group is mentioned.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" \"ETHNIC GROUP\": []", {}]], [607, "1).", [" It is unclear what \"1)\" refers to in the context of the provided information. There is no mention of any specific entity or ethnic group in the given text.", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was mentioned in the text.", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"ETHNIC GROUP\": [\"Not specified\"]\n\nThis passage does not mention any specific ethnic group. It only refers to the administration of alcohol and anticoagulant therapy in general.", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" \"ETHNIC GROUP\": [\"Chinese\"]\n\n\"ETHNIC GROUP\": [\"Asian\"]\n\n\"ETHNIC GROUP\": [\"Other\"]\n\n(Note: Danshen is also known as Salvia miltiorrhiza, Ginkgo biloba is a tree native to China, and Dong quai is also known as Angelica sinensis. These are all traditional Chinese herbs.)", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {}", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" No ethnic group mentioned in the text.", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about any specific ethnic group related to the mentioned entities (Anthocyanins, delphinidin-3-sambubioside, cyanidin-3-sambubioside, and HS).", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific reference to an ethnic group.", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" It is unclear what \"7.2\" refers to in the given context and it does not contain any information about ethnic groups.", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" This passage does not contain any specific ethnic group references. Therefore, the \"ETHNIC GROUP\" field should be left empty.\n\n{\"ETHNIC GROUP\": []}\n\nRegarding the table, it provides information on cholesterol-lowering interventions and their effects on total cholesterol, HDL-C, LDL-C, and triglycerides. However, it does not mention any specific ethnic groups.", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" \"ETHNIC GROUP\": []\n\n(No ethnic group information was provided in the text)", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" No specific ethnic group mentioned in this text.", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"ACE (Angiotensin-Converting Enzyme)\": [\"\"]\n\"adipocyte\": [\"\"]\n\"Akt\": [\"\"]\n\"calcium\": [\"\"]\n\"cyclooxygenase\": [\"\"]\n\"endothelium\": [\"Endothelium-derived relaxant pathways\"]\n\"ERK (Extracellular signal-regulated kinase)\": [\"\"]\n\"Hypotensive activity\": [\"\"]\n\"inhibition\": [\"Inhibition of adipocyte differentiation, Inhibition of calcium influx, Inhibition of ACE, Inhibition of cyclooxygenase\"]\n\"PI3-K (Phosphatidylinositol 3-kinase)\": [\"\"]\n\"saponins (ginsenosides)\": [\"\"]\n\"viscosity (blood)\": [\"Decrease in blood viscosity\"]\n\n\"ETHNIC GROUP\": [\"\"]", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" No specific ethnic group mentioned in the text.", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" No ethnic group information provided in this statement.", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" \"ETHNIC GROUP\": []", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" \"ETHNIC GROUP\": [\"Asian\"] (Schisandra is a plant native to China and other Asian countries)", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" No ethnic group information provided in the text.", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" {\"KEYWORD\": [\"drug metabolism\", \"herb\u2013drug interactions\", \"modelling and simulation\", \"physiologically-based pharmacokinetic (PBPK)\"]}", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" No ethnic group mentioned in the text.", {}]], [631, "Go to: 2.", [" I'm assuming you're asking me to go back to the second paragraph of the text. Here's the information related to entities in that paragraph:\n\nThe following format must be followed:\n{\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]}\n\nThere are three kinds of HMPs in the European Union (regulated in Directive 2001/83/EC and its amendment, Directive 2004/24/EC [12]): (i) products based on \u201ctraditional use\u201d with at least 30 years of documented usage and without known safety concerns, (ii) \u201cwell-established use\u201d, and (iii) HMPs with a regular approval, based on preclinical and clinical data.\n\n{\"ETHNIC GROUP\": [\"European\"]}\n\nThe experiments were carried out after approval by the Animal Ethics Committee of The Chinese University of Hong Kong (Ref No. [51-04-03-01-C-N-01-01]) [13].\n\n{\"ETHNIC GROUP\": [\"Chinese\"]}\n\nThe monograph \u201cginseng radix\u201d in the European Pharmacopoeia names only P. ginseng and defines a minimum content of 4.0% ginsenosides (triterpene saponins) [154].\n\n{\"ETHNIC GROUP\": [\"European\"]}\n\nIn 2007, Zhang reported the switching phenomenon between Traditional Chinese Medicine and sildenafil among impotence patients became common after the application of sildenafil in China [24].\n\n{\"ETHNIC GROUP\": [\"Chinese\"]}\n\nCassia abbreviata is a medium-sized tree that grows in most parts of Africa, especially utilized in Southern African countries such as Botswana, South Africa, Uganda, Zambia, and Zimbabwe.\n\n{\"ETHNIC GROUP\": [\"African\", \"Southern African\"]}", {}]], [632, "2.1.2.", [" It is unclear what \"2.1.2\" refers to in the given context as it does not appear to be a citation or a specific term in the text. Therefore, it cannot be parsed for ethnic groups or other entities.", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" \"ETHNIC GROUP\": [\"Human\"]", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was found in this text.)", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" No ethnic groups found in this text.", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" No ethnic group information provided in the text.", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" \"ETHNIC GROUP\": []", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" \"ETHNIC GROUP\": []", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" No specific ethnic group mentioned in the text.", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this text, there is no explicit mention of an ethnic group. The information provided pertains to the use of Schisandra lignans in Pharmacokinetic (PBPK) simulations and the trials designs.", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or identify entities related to an external file as I don't have the ability to access or process external data. However, if the text mentions a specific file name or file type, I can identify that information. For example:\n\n{\"FILE\": [\"filename.jpg\", \"filetype.pdf\"]}\n\nIn the given context, there is no mention of a specific file name or type.", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" I'm unable to determine an ethnic group from the given text.\n\n\"MBI, mechanism-based inhibition\" is a pharmacological term and does not refer to an ethnic group.", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis passage does not mention any specific ethnic group.", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis limitation does not refer to any specific ethnic group.", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text)", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" \"ETHNIC GROUP\": []\n\nThis statement does not provide any information about ethnic groups.", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"ETHNIC GROUP\": [\"Rats\"]", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" \"ETHNIC GROUP\": []\n\nThis passage does not provide any information about ethnic groups.", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group was mentioned in the context of the mentioned entities \"Danshen/Gegen\" which refer to traditional Chinese medicines, namely Salvia miltiorrhiza and Scrophularia nigra.)", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" \"ETHNIC GROUP\": [\"North American\"] (Sigma-Aldrich is a US-based company)", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" This text does not contain any specific ethnic group references.", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any reference to an ethnic group.", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in this sentence)", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" No ethnic group information provided.", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about ethnic groups related to Danshen, Gegen, or warfarin.", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" \"ETHNIC GROUP\": []\n\nThis passage does not provide any information about ethnic groups. It is discussing the results of a study on rats.", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"ETHNIC GROUP\": [\"European\"] (assuming the literature being referred to is of European origin)\n\nHowever, it's important to note that the case reports mentioned are not specifically stated to be of European origin, so it's possible that they come from other regions as well. The information provided only indicates that there are no clinical reports in the literature specifically related to the interactions between Gegen (a traditional Chinese medicine) and warfarin from European sources.", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"ENTITIES\": [\"CYP enzymes\"]\n\n\"ETHNIC GROUP\": []\n\nNote: CYP enzymes are not specific to any ethnic group.", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"ETHNIC GROUP\": [\"Rats\", \"Human\"]", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" No specific ethnic group mentioned in the text.", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about the ethnic group related to Danshen.", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group was mentioned in the provided context.)", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about any specific ethnic group.", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" No specific ethnic group mentioned in this text.", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about ethnic groups related to the mentioned entities.", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" \"ETHNIC GROUP\": [\"\"]\n\n(In this context, no specific ethnic group is mentioned in the text.)", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" \"ETHNIC GROUP\": [\"\"]}", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" \"ETHNIC GROUP\": [\"Human\"]", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" No entities found in this statement.", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" No ethnic group information provided in the text.", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" \"ETHNIC GROUP\": []", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"ETHNIC GROUP\": [\"Not specified\"]\n\nThe text does not provide specific information about ethnic groups related to the use of medicinal herbs or traditional medicines. The information provided in the text is about the use of herbs and dietary supplements as alternatives to conventional medications, which is a common practice among chronically ill patients or patients with terminal diseases, regardless of ethnicity.", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"ETHNIC GROUP\": [\"African\", \"Indian\"]", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group.", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" \"ETHNIC GROUP\": [\"Tropical\"]}", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" No ethnic group information provided in this sentence.", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" \"ETHNIC GROUP\": [\"German\"]", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" \"ETHNIC GROUP\": [\"European\"] (References are from European researchers)", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" No ethnic group information provided.", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" \"IC\": [\"Fifty percent inhibitory concentration\"]\n\"A\": [\"log of concentration of aqueous extract of herb in the incubations\"]\n\n\"ETHNIC GROUP\": []\n\nNote: No ethnic group information was provided in the text.", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" \"ETHNIC GROUP\": [\"African\", \"Asian\"] (Assuming the authors are of diverse ethnic backgrounds)", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" \"ETHNIC GROUP\": [\"Human\"]\n\n\"PLANTS\": [\"Musa sapientum\", \"Tetracarpidium conophorum\", \"Allium sativum\"]", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis passage does not provide any information about ethnic groups.", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" \"ETHNIC GROUP\": [\"None\"]\n\nThe term \"Allium sativum\" refers to garlic, which is a plant species and does not belong to any specific ethnic group.", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Moringa oleifera is a tree native to India, but it is now widely cultivated in various parts of the world including Africa, Asia, and the Americas.)", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis information does not provide any details about ethnic groups. It only mentions the authors of a study.", {}]], [689, "(2000).", [" This is not an ethnic group. It is a year.", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide enough information to determine an ethnic group related to Gongronema latifolium and Alstonia boonei.", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" \"ETHNIC GROUP\": [\"Indian\"]", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" No ethnic group information provided in the text.", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" \"ETHNIC GROUP\": [\"Indian\"]}", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" \"ETHNIC GROUP\": [\"\"]\n\n(This information does not provide any specific ethnic group information)", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" \"ETHNIC GROUP\": []\n\nIn this context, no specific ethnic group is mentioned.", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" No ethnic group information provided in this statement.", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" No ethnic group information provided in the text.", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" No specific ethnic group mentioned in this statement.", {}]], [701, "A difference was considered significant at P < 0.05.", [" No ethnic group information provided.", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" \"ETHNIC GROUP\": [\"Volunteer\"]\n\nThis information does not specify the ethnicity of the volunteer.", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" No specific ethnic group mentioned in the text.", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" {\"ETHNIC GROUP\": [\"Not specified in the text\"]}", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" No specific ethnic group mentioned in the text.", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" This text does not provide any information about ethnic groups.", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about the ethnic group related to echinacea or policosanol.", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"ETHNIC GROUP\": [\"Not specified in the text\"]\n\nThis passage does not provide any information about a specific ethnic group. The CYP2C9 gene is found in all human populations.", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" No ethnic group information provided in this statement.", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis table does not provide information about ethnic groups.", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" \"ETHNIC GROUP\": []", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" No ethnic groups mentioned in the text.", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis information does not provide any details about ethnic groups. It only refers to the authors of a scientific paper.", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" No ethnic group information provided.", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"ETHNIC GROUP\": [\"Jamaican\"]", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"ETHNIC GROUP\": [\"European\", \"Asian\"] (for Panax ginseng)", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" \"CYP1A2\": [\"\"]\n\n\"phytochemicals\": [\"\"]\n\n\"impact\": [\"affect\", \"influence\"]\n\n\"activity\": [\"enzymatic activity\"]\n\n\"CYP1A2\": {\n  \"\": [\"CYP1A2\"]\n}\n\n\"phytochemicals\": {\n  \"\": [\"phytochemical\"]\n}", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" No specific ethnic group mentioned in the text.\n\n{\"ETHNIC GROUP\": []}", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" \"ETHNIC GROUP\": [\"Jamaican\"]", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" No specific ethnic group mentioned in the text.", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" No ethnic group information provided.", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" \"ETHNIC GROUP\": [\"British\"]", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis passage does not provide any information about ethnic groups. It is about screening natural products for cytochrome P450 inhibition potential with a focus on specific P450 enzymes.", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" It is unclear what entity is referred to in reference [35]. Therefore, no information can be provided for this field.\n\n{\"ETHNIC GROUP\": []}", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" \"ETHNIC GROUP\": []\n\nThis passage does not contain any specific reference to an ethnic group.", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" \"ETHNIC GROUP\": [\"\"]\n\n(The text does not provide information about the ethnic group related to H. verticillata.)", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" No ethnic group information provided in the text.", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" It is not clear in the provided context if \"Worse than the Disease?\" refers to an ethnic group or a specific entity. Therefore, no information can be added to the format for this term.", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or identify entities related to an external file as I don't have the ability to access or process external data. However, if the text mentions a specific file name or type of file, I can identify that information. For example:\n\n{\"FILE\": [\"filename.jpg\", \"file.pdf\"]}\n\nIn the given context, there is no mention of a specific file name or type.", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" No ethnic group information provided in the text.", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" \"ETHNIC GROUP\": [\"Not applicable\"]", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was provided in the text.", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" \"OS\": [\"Oxidative Stress\"]\n\n\"SELECTED SINGLE HERBS\": []\n\n\"Wen Bing Formulas\": []", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis information does not provide any details about ethnic groups.", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis information does not provide any mention of ethnic groups.", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was found in the given text.", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" \"ETHNIC GROUP\": [\"Rats\"]", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" \"ETHNIC GROUP\": [\"Rat\"]", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" No specific ethnic group mentioned in the text.", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" {}\n\n\"ETHNIC GROUP\": []\n\nThis passage does not provide any information about ethnic groups.", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" \"ETHNIC GROUP\": []\n\nThe text does not provide any information about ethnic groups related to the mentioned herbs or herbal components (OS, anti-influenza herbs, or herbal components).", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" This passage does not provide any information about ethnic groups.", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" { \"ETHNIC GROUP\": [] } (No specific ethnic group mentioned in this context)", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" It is unclear what \"S8\" refers to in the given context, as it does not appear to be a recognized ethnic group or geographical location. Therefore, it should not be included in the output.", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis passage does not mention any specific ethnic group.", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" \"ETHNIC GROUP\": [\"Rat\"]", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" \"ETHNIC GROUP\": [\"Rat\"]", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis statement does not refer to any specific ethnic group.", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this text, there is no explicit mention of an ethnic group. The information provided pertains to various locations such as Africa, specifically Southern African countries, and the development of a pharmacokinetic model.", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"ETHNIC GROUP\": [\"\"]\n\nThe given information does not specify an ethnic group. It refers to the botanical name Radix Isatidis, which is the root of Isatis indigotica.", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" \"ETHNIC GROUP\": [\"European\"] # Arctium lappa is native to Europe and Asia.", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" \"ETHNIC GROUP\": [\"Clinical breast cancer patients\"]", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" \"ETHNIC GROUP\": []\n\nThis conclusion does not mention any specific ethnic group.", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group was mentioned in the text.)", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" \"ETHNIC GROUP\": [\"European\", \"Asian\"]} (for Citrus aurantium L. and Phellodendron amurense Rupr.)\n\n\"ETHNIC GROUP\": [\"African\"]} (for Cassia abbreviata and Anemarrhena asphodeloides Bunge)", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" \"ETHNIC GROUP\": [\"European\", \"Asian\"]\n\nThe mentioned plants, Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), and Lilyturf (Ophiopogon japonicus), have their origins in different regions. While Licorice is native to Europe and Central Asia, Ginger originates from South Asia, and Lilyturf is native to East Asia.", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" {\"ETHNIC GROUP\": []}", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about the ethnic group of the researchers or the location of the study.", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific reference to an ethnic group.", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" \"ETHNIC GROUP\": [\"European\"]", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"ETHNIC GROUP\": []\n\nEntities mentioned in the text:\n\n* TAM-resistant cell line MCF-7 tam-R\n* Ethyl acetate extract of Vitex negundo L. (10 Evn-50)\n* TAM (Tamoxifen)\n* MCF-7/TAM-R cells\n\nThere is no explicit mention of any ethnic group in the text.", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {\"ETHNIC GROUP\": [\"Korean\"]}", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {}", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"ETHNIC GROUP\": [\"\"]\n\nIn this text, there is no explicit mention of an ethnic group.", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" No ethnic group information found in the text.", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" \"ENTITY\": [\"GA\", \"PCA\", \"OAT1/3\", \"MDR1\", \"BCRP\"]\n\n\"ENTITY_TYPE\": [\"compound\", \"transporter\"]\n\n\"ETHNIC GROUP\": []", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" \"ETHNIC GROUP\": [\"Global\"]", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" No ethnic group information provided in this statement.", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" No ethnic group information provided in the text.", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"ETHNIC GROUP\": []", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" No ethnic groups found in this text.", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" No specific ethnic group mentioned in the text.\n\n{\"ETHNIC GROUP\": []}", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" No ethnic group information provided in the text.", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" No specific ethnic group information is provided in the text.\n\n{\"ETHNIC GROUP\": []}", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"ETHNIC GROUP\": [\"Rats\"]", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about any specific ethnic group.", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" \"ETHNIC GROUP\": [\"Humans\"]", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" \"ETHNIC GROUP\": [\"Chinese\"]", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" \"ETHNIC GROUP\": []", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" No specific ethnic group mentioned in this text.", {}]], [785, "Click here for additional data file.", [" I cannot follow the link provided to obtain additional information about the cited entities. The information provided in the text is sufficient for parsing the cited entities. Therefore, I will not add any additional data to the current response.\n\n{\"ETHNIC GROUP\": [\"European\", \"Chinese\", \"Southern African\"]}", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" No ethnic group information provided in this text.", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" No ethnic group information provided.", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" No specific ethnic group mentioned in this statement.", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" No ethnic group information provided in this statement.", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" No specific ethnic group mentioned in the text.", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" \"ETHNIC GROUP\": [\"Human\"]", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"ETHNIC GROUP\": []\n\nThe text does not mention any specific ethnic group related to the entities mentioned.", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" No specific ethnic group mentioned in this text.", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" No specific ethnic group mentioned in the text.", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" \"ETHNIC GROUP\": []\n\nNo specific ethnic group was mentioned in the text.", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" \"ETHNIC GROUP\": [\"R.A.\"]", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" \"ETHNIC GROUP\": [\"Korean\"]", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"ETHNIC GROUP\": [\"American\"]", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" No specific ethnic group mentioned in this statement.", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" \"ETHNIC GROUP\": [\"Japanese\"]", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis information does not provide any reference to an ethnic group.", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis information does not specify an ethnic group. The term \"respondents\" is not indicative of ethnicity.", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about any specific ethnic group in relation to grapefruit or felodipine.", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" {\"ETHNIC GROUP\": [\"\"]}\nThese entities do not refer to any specific ethnic group. They are common names of various plants used in traditional medicine.", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: Phytoestrogens and celery are of plant origin and do not refer to any specific ethnic group.)", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" No specific ethnic group mentioned in this text.", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" \"ETHNIC GROUP\": [\"Not specified in text\"]", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"ETHNIC GROUP\": [\"Human\"]", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: No specific ethnic group was mentioned in relation to the use or association with manic psychosis from chronic use of ginseng.)", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" \"ETHNIC GROUP\": [\"Pacific Islanders\"]\n\nExplanation: Kava is a traditional beverage used in Pacific Island cultures, particularly in Fiji, Tonga, and Samoa. The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes.", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" \"ETHNIC GROUP\": [\"Pacific Islanders\"]\n\nExplanation: Kava is a traditional beverage that has been used for centuries in the Pacific Islands for its central nervous system (CNS) benefits. Therefore, the ethnic group associated with its traditional use is Pacific Islanders.", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" \"ETHNIC GROUP\": [\"European\"] (assuming the 18 health volunteers are of European descent)", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"ETHNIC GROUP\": [\"Not specific\"]\n\nNote: Kratom is used in various cultures and regions, but no specific ethnic group was mentioned in the text.", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" \"ETHNIC GROUP\": []", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis information does not provide any details about ethnic groups. The study was conducted on healthy subjects.", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" \"ETHNIC GROUP\": []", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" No specific ethnic group mentioned in the text.", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" \"ETHNIC GROUP\": [\"Human\"]", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" \"ETHNIC GROUP\": [\"North American (echinacea)\", \"Asian (ginseng, rhodiola, terminalia/commiphora ayurvedic mixture)\", \"European (ginseng, St. John\u2019s wort)\", \"Unknown (celery, hydroxycut, kava, kratom, moringa, piperine, valerian)\"]", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group.", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" \"ETHNIC GROUP\": [\"Not applicable\"]", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" \"ETHNIC GROUP\": []", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any details about ethnic groups.", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" No ethnic group information provided.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" No specific ethnic group mentioned in this statement.", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {\"AUTHOR\": [\"MK\"]}", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" {\"ETHNIC GROUP\": []}", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" \"ETHNIC GROUP\": []", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" {\"ETHNIC GROUP\": [\"\"]}\n\n(Note: No specific ethnic group information was provided in the text regarding Parsley.)", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" \"ETHNIC GROUP\": []", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Parsley is a common food and herb used worldwide, no specific ethnic group mentioned in the text.)", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" No ethnic group information provided.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" No ethnic group information provided.", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" \"ETHNIC GROUP\": []", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" No ethnic group information provided.", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" \"ETHNIC GROUP\": [\"\"]\n\nThe text does not provide information about any specific ethnic group related to Epimedium sagittatum or sildenafil.", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" \"ETHNIC GROUP\": []\n\nThis information does not refer to an ethnic group. It is a botanical reference to the plant species Zizyphus jujuba and Corossolus et Zucc. (C. caffra and C. africana).", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" \"ETHNIC GROUP\": [\"\"]\n\n(Note: Epimedium sagittatum is a plant and does not refer to an ethnic group.)", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" No ethnic group information provided.", {}]], [841, "Maxim extract are available from the authors.", [" No ethnic group information provided in the text.", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"ETHNIC GROUP\": [\"European\"]", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" This statement does not refer to any specific ethnic group.", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" No specific ethnic group mentioned in this statement.", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" No specific ethnic group information is provided in this statement.", {}]], [846, "They found a prevalence of 56.6%.", [" It is unclear what is being referred to as \"they\" and \"they found a prevalence of 56.6%\" in this context. Therefore, no ethnic group can be determined from this information.", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" \"ETHNIC GROUP\": [\"Not specified\"]", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" \"ETHNIC GROUP\": [\"Canadian\", \"American\"]", {}]], [849, "A Spanish study reports Aloe vera [37].", [" \"ETHNIC GROUP\": [\"Spanish\"]", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to a specific ethnic group. It is a general statement about potentially hepatotoxic herbs.", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group mentioned in the text)", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"ETHNIC GROUP\": []\n\nNo ethnic group information was provided in the text regarding the patient who experienced liver injury.", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" No ethnic group information provided.", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to a specific ethnic group. Cannabis is a plant that is used for medicinal and recreational purposes in various parts of the world.", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"ETHNIC GROUP\": []", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" \"ETHNIC GROUP\": [\"European\"]", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" \"ETHNIC GROUP\": [\"European\"] (The European Pharmacopoeia sets the standard for the ginkgolic acid content in the refined quantified dry extract)", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No ethnic group information was mentioned in the provided text)", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" No ethnic group information provided in the text.", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" {\"ETHNIC GROUP\": []}", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" \"ETHNIC GROUP\": [\"Korean\"] (assuming Seong is a Korean name)", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"ETHNIC GROUP\": [\"European\"]", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"ETHNIC GROUP\": [\"These groups\"]\nThe specific ethnic groups are not mentioned in the text.", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" \"ETHNIC GROUP\": [\"Rats\"]", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"ETHNIC GROUP\": [\"\"]\n\nThis statement does not provide enough information to determine the ethnic group. It refers to the individual patient's genetic susceptibility, which is not specified by ethnicity in this context.", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" \"CY3A4\" and \"2C9\" are enzymes.\n\n{\"ENZYMES\": [\"CY3A4\", \"2C9\"]}", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" \"ASA\": [\"Acetylsalicylic acid\"]\n\"ETHNIC GROUP\": []", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" No specific ethnic group mentioned in the text.", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" \"ETHNIC GROUP\": []", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" \"ETHNIC GROUP\": [\"\"]\n\nThis statement does not refer to a specific ethnic group. It is a general statement about patients.", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"ETHNIC GROUP\": [\"German\"]", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" {\"ETHNIC GROUP\": [\"\"]}\n\nThis statement does not refer to a specific ethnic group. It is a general warning about potential errors in translating or identifying the correct species based on the text.", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" This statement is not related to any specific ethnic group.", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" \"ETHNIC GROUP\": []", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" \"ETHNIC GROUP\": []\n\nThis statement does not refer to any specific ethnic group. It is a general statement about herb-drug interactions.", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"DRUGS\": []\n\"ETHNIC GROUP\": []", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" \"ETHNIC GROUP\": []\n\nThe text does not provide information about the ethnic group related to the described entity (Cassia abbreviata and its sulfur compounds).", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text regarding the use of this herb for diabetic treatment.)", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" \"ETHNIC GROUP\": [\"Individuals with diabetes\"]", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" \"ETHNIC GROUP\": [\"\"]\n\n(No specific ethnic group information was mentioned in the text regarding Lycium and antidiabetics interaction)", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" \"ETHNIC GROUP\": [\"\"]}\n\nThis statement does not provide any information about ethnic groups. It is discussing the potential effect of Lycium (Goji berry) in combination with conventional antidiabetics.", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" {}", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" \"ETHNIC GROUP\": [\"N/A\"]\n\n\"SYSTEM-TO-SYSTEM OR SYSTEMS BIOLOGY\": [\"system-to-system or systems biology methodology\"]\n\n\"COMPLEX HERBAL INTERVENTIONS\": [\"complex herbal interventions\"]", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" No specific ethnic group mentioned in the text.", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" This statement does not refer to any specific ethnic group.", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"ETHNIC GROUP\": [\"Not specified in the text\"]", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" \"ETHNIC GROUP\": []\n\nThis information does not provide any specific ethnic group information.", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"ETHNIC GROUP\": []", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" {\"ETHNIC GROUP\": [\"\"]}", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" No ethnic groups found in this statement.", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" No ethnic group information found in this text.", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" \"ETHNIC GROUP\": []", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" {\"ETHNIC GROUP\": []} (No specific ethnic group mentioned in the text)", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" No ethnic group information provided.", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" \"ETHNIC GROUP\": [\"Human\"]", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" No ethnic group information provided in this statement.", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" \"ETHNIC GROUP\": [\"\"]\n\n(As Asafetida is a gum resin obtained from various Ferula species, it does not correspond to any specific ethnic group.)", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" No specific ethnic group mentioned in the text.", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" No specific ethnic group mentioned in this text.", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"ETHNIC GROUP\": [\"List of ethnic groups found in text\"]}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.\nThere are three kinds of HMPs in the European Union (regulated in Directive 2001/83/EC and its amendment, Directive 2004/24/EC [12]): (i) products based on \u201ctraditional use\u201d with at least 30 years of documented usage and without known safety concerns, (ii) \u201cwell-established use\u201d, and (iii) HMPs with a regular approval, based on preclinical and clinical data. [/INST]{\"ETHNIC GROUP\": [\"European\"]}</s> [INST] The experiments were carried out after approval by the Animal Ethics Committee of The Chinese University of Hong Kong (Ref No. [/INST]{\"ETHNIC GROUP\": [\"Chinese\"]}</s> [INST] The monograph \u201cginseng radix\u201d in the European Pharmacopoeia names only P. ginseng and defines a minimum content of 4.0% ginsenosides (triterpene saponins) [154]. [/INST]{\"ETHNIC GROUP\": [\"European\"]}</s> [INST] In 2007, Zhang reported the switching phenomenon between Traditional Chinese Medicine and sildenafil among impotence patients became common after the application of sildenafil in China [24]. [/INST]{\"ETHNIC GROUP\": [\"Chinese\"]}</s> [INST] Cassia abbreviata is a medium-sized tree that grows in most parts of Africa, especially utilized in Southern African countries such as Botswana, South Africa, Uganda, Zambia, and Zimbabwe. [/INST]{\"ETHNIC GROUP\": [\"Southern African\"]}</s> [INST] TEXT HERE [/INST]"}